|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
Infertility is a disease of the reproductive system. It is defined for most couples as not being able to get pregnant or maintain a pregnancy despite having frequent, unprotected, appropriately timed intercourse for at least a year. It is estimated that during their primary reproductive years, that 10 to 15 percent of couples in the United States are infertile. This condition affects both women and men. It is believed that almost 7 million women and 4 million men are affected by infertility.
Module 4 will conclude with addressing some of the special considerations in patients with infertility issues. The role of the specialty pharmacy and the pharmacy care plan along with issues of adherence will also be discussed. Future trends in assisted reproductive technology will also be presented.
The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:
- Review the expanding role of patients using Assisted Reproductive Technologies (ART) services.
- Discuss how the patient is unique within specialty pharmacy care.
- Identify barriers to adherence and compliance to treatment plan for infertility.
- Review the cost of medications - cash vs. managed care considerations.
- Discuss current and future trends in ART treatments.
Ann Scalia, BSN, RN, CNOR
Manager- Clinical Education Specialists
AllianceRx Walgreens Prime
Nancy Harrington, RNC-REIN
Senior Specialist Clinical Education
AllianceRx Walgreens Prime
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Ann Scalia and Nancy Harrington are employees of AllianceRx Walgreens Prime.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 04-05-2019
Expiration Date: 04-05-2022
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-132-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 0.75 contact hour (0.075 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.